Product information
From Health Canada
The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.
Current status:
Approved
Current status date:
2018-11-07
Product name:
KAMRAB
Description:
10 ML VIAL
DIN:
02482509
Product Monograph/Veterinary Labelling:
Date:
2018-11-07
Product monograph/Veterinary Labelling (PDF version ~ 175K)
Company:
KAMADA LTD
2 Holzman St.
Kiryat Weizmann Science Park
Rehovot
Israel
7670402
Class:
Human
Dosage form(s):
Solution
Route(s) of administration:
Intramuscular
Number of active ingredient(s):
1
Schedule(s):
Schedule D
American Hospital Formulary Service (AHFS): See footnote 3
80:04.00
Anatomical Therapeutic Chemical (ATC): See footnote 4
J06BB05 RABIES IMMUNOGLOBULIN
Active ingredient group (AIG) number:See footnote5
0110666002
| Active ingredient(s) | Strength |
|---|---|
| RABIES IMMUNOGLOBULIN (HUMAN) | 150 UNIT / ML |
Risk Management Plans See footnote 7
A Risk Management Plan (RMP) for this product was submitted.